Literature DB >> 21105989

Preferences for antimuscarinic therapy for overactive bladder.

Paul Swinburn1, Andrew Lloyd, Shehzad Ali, Noreen Hashmi, David Newal, Hiba Najib.   

Abstract

OBJECTIVE • To examine patient preferences and strength of preferences for treatment for the various symptoms of overactive bladder and adverse events associated with the use of antimuscarinic treatments. PATIENTS AND METHODS • A discrete choice experiment (DCE) survey was developed that detailed treatment choices in terms of attributes relating to their efficacy in reducing symptoms and the likelihood of experiencing typical adverse events. Levels for each attribute were based on a literature review, qualitative interviews and a meta-analysis of clinical trial data. • Attributes were combined into choice sets using a fractional orthogonal design that had been folded over. Pairs of choice sets were presented to overactive bladder (OAB) patients (n= 332), who indicated which treatment alternative they preferred. Data were analysed using the conditional logit model. RESULTS • Participants expressed the strongest preference for the avoidance of urgency incontinence episodes, followed by preference for a reduction in the experience of urinary urgency and the number of micturition episodes. The influence of the likelihood of experiencing an adverse event on treatment preference was also estimated. • Finally, marginal rates of substitution were calculated to demonstrate the relative value of trade-offs between the various attributes. • Treatment preferences were found to be broadly similar across two patient age groups (i.e. under 45 s and 45 and over). CONCLUSION • The study demonstrates that individuals with OAB place significant emphasis on the prospect of reduction in symptoms. Avoidance of incontinence episodes is particularly valued and equivalent to a much greater reduction in the frequency of micturition or experience of urgency. However, even a modest increase in the likelihood of experiencing an adverse event could easily motivate a change in treatment preference.
© 2010 OXFORD OUTCOMES LTD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21105989     DOI: 10.1111/j.1464-410X.2010.09882.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

Review 1.  Risk as an attribute in discrete choice experiments: a systematic review of the literature.

Authors:  Mark Harrison; Dan Rigby; Caroline Vass; Terry Flynn; Jordan Louviere; Katherine Payne
Journal:  Patient       Date:  2014       Impact factor: 3.883

2.  Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment.

Authors:  Veerle H Decalf; Anja M J Huion; Dries F Benoit; Marie-Astrid Denys; Mirko Petrovic; Karel C M M Everaert
Journal:  Drugs Aging       Date:  2017-08       Impact factor: 3.923

3.  Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.

Authors:  Mike Herdman; Jameel Nazir; Zalmai Hakimi; Emad Siddiqui; Moses Huang; Marco Pavesi; Scott MacDiarmid; Marcus J Drake; Nancy Devlin
Journal:  Patient       Date:  2017-12       Impact factor: 3.883

4.  Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States.

Authors:  Stephen R Kraus; Junlong Li; Rita M Kristy; Amy Lockefeer; Hongbo Yang; Mo Zhou; David R Walker
Journal:  J Int Med Res       Date:  2022-05       Impact factor: 1.573

Review 5.  Discrete choice experiments in health economics: a review of the literature.

Authors:  Michael D Clark; Domino Determann; Stavros Petrou; Domenico Moro; Esther W de Bekker-Grob
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

6.  Men's preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment.

Authors:  Colette Mankowski; Divine Ikenwilo; Sebastian Heidenreich; Mandy Ryan; Jameel Nazir; Cathy Newman; Verity Watson
Journal:  Patient Prefer Adherence       Date:  2016-11-24       Impact factor: 2.711

7.  Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain.

Authors:  Antoni Sicras-Mainar; Javier Rejas; Ruth Navarro-Artieda; Alba Aguado-Jodar; Amador Ruiz-Torrejón; Jordi Ibáñez-Nolla; Marion Kvasz
Journal:  BMC Urol       Date:  2013-10-21       Impact factor: 2.264

8.  A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US.

Authors:  Amod Athavale; Katherine Gooch; David Walker; Marissa Suh; Jillian Scaife; Ali Haber; Nandini Hadker; Roger Dmochowski
Journal:  Patient Prefer Adherence       Date:  2018-10-12       Impact factor: 2.711

Review 9.  Delivering patient-centered care through shared decision making in overactive bladder.

Authors:  Roshan Paudel; Giulia I Lane
Journal:  Neurourol Urodyn       Date:  2022-03-25       Impact factor: 2.367

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.